肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗

2015-01-13 MedSci MedSci原创

PD-1非小细胞肺癌
关注

Bristol-Myers Squibb最新PD1抑制药物ornivolumab（Opdivo），原本用于黑色素瘤，最新一项研究用于鳞状非小细胞肺癌的结果显示，在总生存期方面显著优于传统的化疗药物紫杉醇，该试验在早期阶段即中止研究，所有对照组患者全部转向ornivolumab治疗。这项研究给鳞状非小细胞肺癌的治疗带来巨大的变化，这是鳞状非小细胞肺癌近几十年来最大的突破之一。该药物有望被FDA优先审


Bristol-Myers Squibb最新PD1抑制药物ornivolumab（Opdivo），原本用于黑色素瘤，最新一项研究用于晚期鳞状非小细胞肺癌的结果显示，在总生存期方面显著优于传统的化疗药物紫杉醇，该试验在早期阶段即中止研究，所有对照组患者全部转向ornivolumab治疗。

这项研究给鳞状非小细胞肺癌的治疗带来巨大的变化，这是鳞状非小细胞肺癌近几十年来最大的突破之一。该药物有望被FDA优先审批。

有评论认为：这是医学的胜利，这是科学的胜利，也是我们人类文明的胜利。肿瘤免疫治疗伟大的一天！五年生存率不到百分之二十的非小细胞肺癌，PD1单抗临床试验中期结果分析发现免疫治疗实验组生存远超化疗药紫杉醇对照组，实验马上終止，对照组病人全体改用免疫治疗。

小知识：
PD-1(programmed death 1)程序性死亡受体1，是一种重要的免疫抑制分子。为CD28超家族成员,其最初是从凋亡的小鼠T细胞杂交瘤2B4.11克隆出来。以PD-1为靶点的免疫调节对抗肿瘤、抗感染、抗自身免疫性疾病及器官移植存活等均有重要的意义。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-02-22 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-04-26 智智灵药

    #非小细胞#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-21 loveios

    EN

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-14 xiongliangxl

    #PD-1抑制剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-13 MedSci客户端朋友

    breaking news

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1851220, encodeId=429f1851220b3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 22 22:38:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059492, encodeId=821d20594928c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Apr 26 18:38:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14534, encodeId=3fd81453400, content=EN, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1aae1611537, createdName=loveios, createdTime=Wed Jan 21 11:59:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed Jan 14 15:38:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14045, encodeId=6be81404536, content=breaking news, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端朋友, createdTime=Tue Jan 13 08:07:00 CST 2015, time=2015-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14047, encodeId=c9831404ec7, content=PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jan 13 08:06:00 CST 2015, time=2015-01-13, status=1, ipAttribution=)]
    2015-01-13 lovetcm

    PD-1和PD-L1抑制剂将开创肿瘤治疗的新纪元，对以往很多疗效不佳的肿瘤，可能都能展示出独特的疗效

    0

相关资讯

PD-1通路可能成为NSCLC治疗的里程碑式靶标

在第15届世界肺癌大会上，多位专家纷纷评论道：前期免疫治疗充满希望的结果使非小细胞肺癌(NSCLC)治疗进入了“令人振奋的时代”。来自加拿大安大略省汉密尔顿McMaster大学Peter Ellis教授更是表示：“在治疗该肿瘤时，利用免疫系统是非常有前途的事儿。”他在会上对三项免疫治疗研究摘要进行了详细的阐述。其中包括三个药物：nivolumab，MK-3475（又名lambrolizumab

Lancet Oncol：Pidilizumab联合利妥昔单抗治疗复发性滤泡状淋巴瘤疗效显著

用PD-1单克隆抗体pidilizumab联合利妥昔单抗治疗，66%的病人产生可见反应，52%的病人完全缓解。没有治疗相关的3-4级有害自身免疫事件产生。抗肿瘤免疫反应可能被肿瘤微环境内的免疫检查点，包括PD-1（程序性细胞死亡-1因子）抑制。PD-1是一种肿瘤T细胞上的联合抑制受体，能损伤T细胞的功能。柳叶刀肿瘤学公布了Westin等的一项临床2期研究报告，评估抗PD-1抗体联合利妥昔单抗治疗复

ASCO 2014：郭军谈PD-1抗体治疗黑色素瘤的2项试验

年入选ASCO年会新闻发布会的黑色素瘤研究共有3项。除我们5月14日推送的有关ipilimumab的一项研究外，还有两项关于PD-1的研究。我们特邀北京大学肿瘤医院郭军教授继续跟我们分享关于这两项研究的故事。 研究一 题目：在411例黑色素瘤患者中抗PD-1单抗MK-3475的有效性和安全性（Efficacy and safety of the anti-PD-1 m

SABCS 2014：PD-1抗体治疗进展期三阴乳腺癌研究

进展期乳腺癌">三阴乳腺癌患者中pembrolizumab(MK-3475)的Ⅰb期研究 摘要号：S1-09 报告时间：圣安东尼奥时间12月10日，10:45 am Pembrolizumab(MK-3475)是一种人源化的IgG4，与PD-1受体有高度亲和力的抗PD-1抗体，能阻断PD-L1和PD-L2的双重配体。 本项Ⅰb期研究显示，Pembrolizumab在难治性、PD-L1

ASH 2014：PD-1治疗复发性经典霍奇金淋巴瘤缓解率达66%

2014年第56届美国血液学会年会（ASH）于12月6日-9日在美国旧金山举行。美国血液学会（ASH）是全球最大的关于血液疾病病因及治疗的专业协会，其使命是能过促进血液学的研究、临床护理、教育、培训及宣传而进一步促进对血液、骨髓、免疫、凝血及脉管系统疾病的了解、诊断与防治。 此次年会上，抗癌免疫疗法PD-1/PD-L1抑制剂是一大热点，年会上，Keytruda展现出了治疗血液肿瘤的潜力。根据年会

ASH 2014：PD-1在血液肿瘤领域展现巨大潜力

根据2014年第56届美国血液学会年会（ASH）上公布的数据，以默沙东Keytruda和百时美施贵宝Opdvio为代表的新一类抗癌免疫疗法PD-1/PD-L1抑制剂在缩小实体肿瘤方面已取得了巨大的成功。现在，这类药物在血液癌症领域也展现出了巨大潜力。 PD-1/PD-L1抑制剂展现血癌治疗潜力 根据会上公布的2项研究数据，对当前任何已获批药物均无治疗反应的晚期霍奇金淋巴瘤（HL）患者，接受Ke